Advertisement

Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States

Published:December 30, 2022DOI:https://doi.org/10.1016/j.clgc.2022.12.008

      Abstract

      Introduction

      We developed a claims-based algorithm to identify patients with von Hippel-Lindau disease–associated renal cell carcinoma (VHL-RCC) from a real-world database and quantified the prevalence, healthcare resource utilization (HRU), and healthcare costs of VHL-RCC in the United States (US).

      Methods

      Using data from the Optum Clinformatics Data Mart (2007-2020), an algorithm was developed to identify patients with VHL-RCC, who were matched to controls without VHL disease or RCC. VHL-RCC prevalence in 2019 was estimated and standardized to the US population. HRU and costs were compared between patients with VHL-RCC versus controls, and costs associated with tumor reduction procedures were estimated among patients with VHL-RCC. All costs were adjusted to 2020 US dollars.

      Results

      VHL-RCC prevalence in the US was 0.92 per 100,000 persons, resulting in 3023 estimated patients with VHL-RCC in the US. The VHL-RCC cohort (N = 160) incurred higher rates of inpatient, outpatient, and emergency department visits versus controls (N = 800), translating to $36,450 more in adjusted all-cause annual healthcare costs. By examining only claims with an associated RCC diagnosis, it was estimated that patients with VHL-RCC incurred $21,123 annually in healthcare costs due to RCC management, and the average cost of nephrectomy was $29,313. Among different complications of RCC-related tumor reduction procedures, end-stage renal disease was the costliest, which incurred $65,338 over 6 months postnephrectomy.

      Conclusion

      VHL-RCC was associated with significant HRU and healthcare costs, including those related to tumor surgeries. This study underscores the importance of novel therapies that can reduce the clinical burden and medical intervention costs of VHL-RCC.

      Keywords

      Abbreviations:

      CCI (Charlson Comorbidity Index), CDM (Clinformatics Data Mart), CI (Confidence interval), CNS (Central nervous system), ED (Emergency department), EHR (Electronic health record), FDA (Food and Drug Administration), GEE (Generalized estimating equation), HIPAA (Health Insurance Portability and Accountability Act), HRU (Healthcare resource utilization), ICD (International Classification of Diseases), IRR (Incidence rate ratios), RCC (Renal cell carcinomas), TRP (Treatment reduction procedures), US (United States), VHL (Von Hippel Lindau)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Glasker S
        • Vergauwen E
        • Koch CA
        • Kutikov A
        • Vortmeyer AO.
        Von Hippel-Lindau Disease: current challenges and future prospects.
        Onco Targets Ther. 2020; 13: 5669-5690
        • Maher ER
        • Iselius L
        • Yates JR
        • et al.
        Von Hippel-Lindau disease: a genetic study.
        J Med Genetics. 1991; 28: 443-447
        • Feletti A
        • Anglani M
        • Scarpa B
        • et al.
        Von Hippel-Lindau disease: an evaluation of natural history and functional disability.
        Neuro Oncol. 2016; 18: 1011-1020
        • Neumann HP
        • Wiestler OD.
        Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus.
        Lancet (London, England). 1991; 337: 1052-1054
        • Evans DG
        • Howard E
        • Giblin C
        • et al.
        Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.
        Am J Med Genetics Part A. 2010; 152a: 327-332
        • Binderup MLM
        • Galanakis M
        • Budtz-Jørgensen E
        • Kosteljanetz M
        • Luise Bisgaard M
        Prevalence, birth incidence, and penetrance of von Hippel–Lindau disease (vHL) in Denmark.
        Eur J Hum Genetics. 2017; 25: 301-307
        • Ganeshan D
        • Menias CO
        • Pickhardt PJ
        • et al.
        Tumors in von Hippel-Lindau Syndrome: from head to toe-comprehensive state-of-the-art review.
        Radiographics. 2018; 38: 982
        • Jonasch E
        • Donskov F
        • Iliopoulos O
        • et al.
        Belzutifan for renal cell carcinoma in von Hippel-Lindau Disease.
        N Engl J Med. 2021; 385: 2036-2046
        • Kim E
        • Zschiedrich S.
        Renal cell carcinoma in von Hippel-Lindau disease-from tumor genetics to novel therapeutic strategies.
        Front Pediatr. 2018; 6: 16
        • Chen SS
        • Al Mawed S
        • Unruh M
        Health-related quality of life in end-stage renal disease patients: how often should we ask and what do we do with the answer?.
        Blood Purif. 2016; 41: 218-224
        • US Food and Drug Administration
        FDA approves belzutifan for cancers associated with von Hippel-Lindau disease.
        2021 (Accessed November 25, 2021)
        • US Census Bureau
        Current Population Survey.
        Annual Social and Economic supplement. 2019 (Accessed November 12, 2021)
        • King T
        • Olufajo O
        • Jain A
        • et al.
        Demographics and management costs of VHL patients with a pheochromocytoma: a national inpatient service analysis.
        J Urol. 2020; 203: e634
        • Kale HP
        • Mays DP
        • Nadpara PA
        • Slattum PW
        • Paul AK
        • Carroll NV.
        Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
        Urol Oncol. 2019; 37: 356.e319-356.e328
        • Lang K
        • Danchenko N
        • Gondek K
        • Schwartz B
        • Thompson D.
        The burden of illness associated with renal cell carcinoma in the United States.
        Urol Oncol. 2007; 25: 368-375
        • Golombos DM
        • Chughtai B
        • Trinh QD
        • et al.
        Minimally invasive vs open nephrectomy in the modern era: does approach matter?.
        World J Urol. 2017; 35: 1557-1568
        • Larcher A
        • Sun M
        • Dell'Oglio P
        • et al.
        Mortality, morbidity and healthcare expenditures after local tumour ablation or partial nephrectomy for T1A kidney cancer.
        Eur J Surg Oncol. 2017; 43: 815-822
        • Chang P
        • Renehan P
        • Taylor KN
        • et al.
        Societal costs of localized renal cancer surgery.
        Can J Urol. 2018; 25: 9401-9406